Riverside Partners has sold BioAgilytix to Cobepa. No financial terms were disclosed. Based in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers and cell-based assay services.
Riverside Partners has sold BioAgilytix to Cobepa
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.). For more information, visit www.bioagilytix.com.
“Lincoln International has extensive Pharma Services knowledge and high credibility with buyers in the space. The Lincoln team added value to our daily business and provided valuable insights to help us continue our industry leading growth and exceptional customer service. I look forward to working with Lincoln International in the future to help us identify future business growth opportunities” stated Jim Datin, CEO of BioAgilytix.
Tony Crisman, Managing Director at Lincoln said, “Lincoln has always been impressed by BioAgilytix and Riverside’s value-added assistance in growing the platform at a rapid pace. We were thrilled to work with the BioAgilytix management team and Riverside on this important initiative. We know Cobepa is the right partner to continue the growth trajectory and lead the Company into the future. We look forward to watching BioAgilytix’s continued success with Cobepa as a partner. Contract Research Organizations, especially those that are highly differentiated and have significant scale like BioAgilytix, continue to be a strong focus of Lincoln and our practice.”
“It has been extremely fulfilling to partner with BioAgilytix and help the company grow into the world-class organization it is today,” said David Belluck, General Partner, Riverside Partners. “BioAgilytix’s success is a testament to the commitment of its management team and employees to solving their customers’ unique scientific challenges. We are proud to have supported the company by significantly growing the scientific organization, meaningfully expanding laboratory capacity, broadening the customer base, completing the acquisition of Hamburg-based IPM Biotech, and implementing best-in-class systems and processes.”
Based in Brussels and New York, Cobepa S.A. (Cobepa) is a privately-held investment company backed by European families. Cobepa manages a diversified portfolio of private equity investments valued at around €2.5 billion. Cobepa invests in leading companies with strong business models, sustainable market positions and strong management teams. For more information, visit www.cobepa.com.